Manfaat Beta Blocker Generasi Ketiga pada Terapi Gagal Jantung

Oleh :

dr.Eduward Thendiono, SpPD,FINASIM

Obat golongan beta blocker generasi ketiga, seperti carvedilol, telah dilaporkan bermanfaat dalam penanganan gagal jantung. Reseptor beta-adrenergik diekspresikan dalam kardiomiosit dan diaktivasi oleh noradrenalin yang dilepaskan dari sinaps simpatik atau katekolamin yang bersirkulasi. Oleh karenanya, penggunaan beta blocker bermanfaat dalam berbagai penyakit kardiovaskuler.

Di pasaran sudah tersedia beragam jenis beta blocker, mulai dari metoprolol, bisoprolol, hingga obat generasi ketiga seperti carvedilol, nebivolol, labetalol, bucindolol, dan celiprolol. Meski sama-sama masuk dalam golongan beta blocker, semua obat tersebut memiliki perbedaan dalam hal selektivitas reseptor beta, efek vasodilatasi, dan fitur tambahan lain misalnya antioksidan.[1]

Carvedilol

(Konten ini khusus untuk dokter. Registrasi untuk baca selengkapnya)

Referensi

1. Do vale GT, Ceron CS, Gonzaga NA, Simplicio JA, Padovan JC. Three Generations of ß-blockers: History, Class Differences and Clinical Applicability. Curr Hypertens Rev. 2019;15(1):22-31. Doi: 10.2174/1573402114666180918102735.
2. National Center for Biotechnology Information. PubChem Compound Summary for CID 2585, Carvedilol. https://pubchem.ncbi.nlm.nih.gov/compound/Carvedilol. Accessed Mar. 9, 2023.
3. Poole-Wilson PA, Swedberg K, Cleland JG, et al, the Carvedilol Or Metoprolol European Trial Investigators. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol or Metoprolol European Trial (COMET): randomised controlled trial. Lancet 2003;362:7-13. https:doi.org/10.1016/s0140-6736(03)13800-7
4. Colucci WS. Landmark study: The Carvedilol Post-Infarct Survival Control in left ventricular dysfunction study (CAPRICORN). Am J Cardiol 2004;93(suppl):13B-16B. https://doi.org/10.1016/j.amjcard.2004.01.018
5. Schwartz B, Pierce C, Madelaire C, Schou M, Kristensen SL, Gislason GH, Køber L, Torp-Pedersen C, Andersson C. Long-Term Mortality Associated With Use of Carvedilol Versus Metoprolol in Heart Failure Patients With and Without Type 2 Diabetes: A Danish Nationwide Cohort Study. J Am Heart Assoc. 2021 Sep 21;10(18):e021310. doi: 10.1161/JAHA.121.021310. Epub 2021 Sep 17. PMID: 34533058; PMCID: PMC8649547.
6. Li T, Yuan G, Ma C, Jin P, Zhou C, Li W. Clinical efficacy of carvedilol treatment for dilated cardiomyopathy: A meta-analysis of randomized controlled trials. Medicine (Baltimore). 2019 May;98(18):e15403. doi: 10.1097/MD.0000000000015403. PMID: 31045794; PMCID: PMC6504318.
7. National Center for Biotechnology Information. PubChem Compound Summary for CID 71301, Nebivolol. https://pubchem.ncbi.nlm.nih.gov/compound/Nebivolol. Accessed Mar. 9, 2023.
8. Fongemie J, Felix-Getzik E. A Review of Nebivolol Pharmacology and Clinical Evidence. Drugs. 2015 Aug;75(12):1349-71. doi: 10.1007/s40265-015-0435-5. PMID: 26177892; PMCID: PMC4541699.
9. Ozaydin M, Yucel H, Kocyigit S, Adali MK, Aksoy F, Kahraman F, Uysal BA, Erdogan D, Varol E, Dogan A. Nebivolol versus Carvedilol or Metoprolol in Patients Presenting with Acute Myocardial Infarction Complicated by Left Ventricular Dysfunction. Med Princ Pract. 2016;25(4):316-22. doi: 10.1159/000446184. Epub 2016 May 10. PMID: 27164841; PMCID: PMC5588427.
10. Easterling T, Mundle S, Bracken H, et al. Oral antihypertensive regimens (nifedipine retard, labetalol, and methyldopa) for management of severe hypertension in pregnancy: an open label, randomised controlled trial. Lancet 2019; 394(10203):1011-1021. Doi: https//doi.org/10.1016/S0140-6736(19)31282-6.
11. Webster LM, et al. Labetalol versus Nifedipine as Antihypertensive treatment for chronic hypertension in pregnancy. Hypertension. 2017; 70:915-922. https://doi.org/10.1161/HYPERTENSIONAHA.117.09972
12. Webster LM Webb AJ, Chappell LC. What is the evidence for using labetalol as a first line treatment option for hypertension in pregnancy? Dtb 2018;56(9). https://dx.doi.org/10.1136/dtb.2018.9.000008
13. Kao DP, Davis G, Aleong R, O'Connor CM, Fiuzat M, Carson PE, Anand IS, Plehn JF, Gottlieb SS, Silver MA, Lindenfeld J, Miller AB, White M, Murphy GA, Sauer W, Bristow MR. Effect of bucindolol on heart failure outcomes and heart rate response in patients with reduced ejection fraction heart failure and atrial fibrillation. Eur J Heart Fail. 2013 Mar;15(3):324-33. doi: 10.1093/eurjhf/hfs181. Epub 2012 Dec 7. PMID: 23223178; PMCID: PMC3576901.
14. Nawarskas JJ, Cheng-Lai A, Frishman WH. Celiprolol: A Unique Selective Adrenoceptor Modulator. Cardiol Rev. 2017 Sep/Oct;25(5):247-253. doi: 10.1097/CRD.0000000000000159. PMID: 28742547; PMCID: PMC5549637.